Quantumzyme Highlights Benefits and Commercialization Opportunities of Pending Breakthrough Green Chemistry Patent
The process utilizes a specially engineered enzyme to streamline ibuprofen production, significantly reducing the use of harsh chemicals, solvents, and energy. By replacing traditional multi-step chemical synthesis with a selective biocatalytic transformation, Quantumzyme's method offers both environmental and economic advantages.
Key Benefits of the Breakthrough Process:
Quantumzyme plans to offer this soon to be patented process across multiple channels:
'Our enzymatic ibuprofen process exemplifies how cutting-edge science can address real-world industrial challenges,' stated Naveen Kulkarni, CEO of Quantumzyme. 'Through strategic commercialization, we aim to help manufacturers achieve regulatory compliance, meet ESG goals, and reduce costs - all while making chemistry greener.'
This breakthrough directly resonates with the scientific momentum sparked by the 2024 Nobel Prize in Chemistry, awarded for advancements in computational enzyme design and protein structure prediction. Like Nobel laureates David Baker, Demis Hassabis, and John Jumper, Quantumzyme leverages artificial intelligence and protein engineering to revolutionize industrial chemistry - delivering sustainable, scalable solutions for the pharmaceutical sector.
By combining green chemistry, computational design, and strategic commercialization, Quantumzyme's goal is to set new standards for the future of sustainable pharmaceutical production.
For the most current information and updates, please visit our website at www.quantumzymecorp.com.
About Quantumzyme Corp.
Quantumzyme Corp. is a pioneering biotransformation company revolutionizing chemical processes through sustainable, enzyme-based solutions. Specializing in green chemistry, it harnesses quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to design high-performance biocatalysts that enhance efficiency, reduce waste, and minimize environmental impact. By integrating computational modeling with wet-lab validation, Quantumzyme delivers scalable, cost-effective biocatalysis solutions that improve industrial sustainability. Offering end-to-end enzyme development services - from discovery and engineering to process optimization and scale-up - Quantumzyme empowers its partners to adopt greener, more efficient production methods. Committed to sustainability and innovation, the company envisions a future where biotechnology drives global solutions for climate change, pollution, and resource efficiency, making eco-friendly biocatalysis the industry standard.
Disclaimer
The information contained in this press release is provided by Quantumzyme Corp. ('Quantumzyme') for general informational purposes only. This release may include forward-looking statements that reflect Quantumzyme's current expectations, estimates, projections, and assumptions about future events, business performance, market conditions, or technological developments. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. Forward-looking statements are based on management's beliefs and assumptions as of the date of this press release and are subject to change without notice.
Quantumzyme makes no representations or warranties, express or implied, regarding the accuracy, completeness, or reliability of the information contained herein. The company undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future developments, or changes in expectations, except as required by applicable law. Past performance should not be taken as an indicator of future results, and readers should not place undue reliance on any projections or expectations presented in this release.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it provide financial, investment, or legal advice. Any references to market trends, scientific advancements, or industry insights are provided for contextual purposes only and should not be interpreted as endorsements, guarantees, or definitive predictions of future developments. Readers and investors are encouraged to conduct their own due diligence and seek independent professional advice before making any investment or business decisions related to Quantumzyme or its affiliates.
Media Contact:
Naveen Kulkarni
Chief Executive Officer
Quantumzyme Corp.
15656 Bernardo Center Drive, Suite 801
San Diego, CA 92127
Phone: +1 (858) 203-0312
Email: [email protected]
Website: www.quantumzymecorp.com
View the original release on www.newmediawire.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
a day ago
- Business Insider
Kepler Capital Remains a Buy on Sandoz Group Ltd (SDZXF)
In a report released on August 7, Nicolas Pauillac from Kepler Capital maintained a Buy rating on Sandoz Group Ltd, with a price target of CHF42.60. The company's shares closed yesterday at $58.24. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Pauillac covers the Healthcare sector, focusing on stocks such as Sanofi, Formycon AG, and COSMO Pharmaceuticals N.V.. According to TipRanks, Pauillac has an average return of 11.7% and a 48.15% success rate on recommended stocks. In addition to Kepler Capital , Sandoz Group Ltd also received a Buy from Barclays's Emily Field in a report issued yesterday. However, on the same day, Jefferies downgraded Sandoz Group Ltd (Other OTC: SDZXF) to a Hold. SDZXF market cap is currently $24.67B and has a P/E ratio of 107.75.
Yahoo
a day ago
- Yahoo
Why Investors Were so High on Curaleaf Stock Thursday
Key Points As is common in the pot industry, Curaleaf posted a net loss in its second quarter. There were several reasons to be optimistic about its future, however. 10 stocks we like better than Curaleaf › Earnings season is always something of a nerve-shredding time for marijuana stock investors, as pot companies more often than not tend to post bottom-line losses. Sure enough, sector mainstay Curaleaf (OTC: CURLF) delivered a deficit in the second quarter, as its earnings release published after market close Wednesday revealed. However, it wasn't significantly deeper on a comparable basis. Meanwhile, there were other glimmers of hope in the document. As a result, bullish investors traded up Curaleaf stock on the day, powering it to a nearly 7% gain. Investor tolerance for loss For the quarter, Curaleaf posted total net revenue of more than $314 million, representing a slide from the over $342 million it earned in the same period of 2024. That net loss, meanwhile, was considerable but not much worse than in the year-ago frame; it deepened to $53 million ($0.07 per share) from nearly $49 million. Curaleaf continued to expand during the quarter, as it flicked the lights on in two dispensaries, one located in populous Florida (specifically the municipality of Winter Park, near Orlando) and the other in Lima, Ohio. On the product side, it launched a pair of new products, Anthem pre-rolled cannabis cigarettes and Select ACE oil. Perhaps more impactfully for the future, it was awarded a license to participate in the specialized marijuana market of another populous location, the country of Turkey. Its license gives it entry to that nation's medical pot market, which began at the end of July with a new law allowing for sales in pharmacies to qualifying patients. Looking for legalization As ever with marijuana stocks, they're probably not going to move significantly -- and sustainably -- until full-blown legalization (or at least decriminalization) is enacted in a major jurisdiction. All eyes are on the U.S., where halting efforts in this sphere have resulted in a patchwork of states where medical and/or recreational weed sale and consumption are permitted. Should you invest $1,000 in Curaleaf right now? Before you buy stock in Curaleaf, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Curaleaf wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $635,544!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,099,758!* Now, it's worth noting Stock Advisor's total average return is 1,046% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Investors Were so High on Curaleaf Stock Thursday was originally published by The Motley Fool Sign in to access your portfolio
Entrepreneur
a day ago
- Entrepreneur
Time to Scale Responsibly
Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. In the early days of India's startup revolution, the narrative was simple:grow fast, scale faster. Today, however, growth without responsibility is no longer viable. As India continues to mint unicorns and cement its place as the third-largest startup ecosystem in the world, Environmental, Social, and Governance (ESG) integration has emerged as a defining driver of purposeful growth. It is no longer a corporate luxury—it is a strategic necessity for building resilient, future-forward businesses that can thrive in a changing world. Startups must embed ESG principles to remain competitive and investment-ready. They possess the agility and freedom from legacy systems when combined with an innovation driven mindset, uniquely positioning them to integrate sustainability into their operations from day one. But Many Don't. In the race for product market fit and funding, ESG is often seen as a 'later stage problem'—a costly oversight. Recent challenges faced by Indian startups show how weak governance can erode trust and stall momentum. ESG goes ESG scrutiny across the broader ecosystem. From FY 2025-26onwards,the top 250 listed companies are encouraged to voluntarily disclose ESG metrics for their value chains, with assessment or assurance applicants from FY 2026-27. The value chain shall encompass top upstream and downstream partners of a listed entity, individually comprising 2% or more of the entity's purchases and sales (by value) respectively; and the listed entity may limit disclosure of value chain to cover 75% of its purchases and sales (by value) respectively. For startups, SEBI's ESG norms carry two implications. First, IPO bound startups must understand how these disclosure requirements beyond emissions and diversity—it's about building resilient, transparent enterprises aligned with today's stakeholders. Investor expectations are equally clear and increasingly aligned across the capital spectrum. Development finance institutions (DFIs) or DFI backed venture capitalists (VCs) are embedding ESG filters into their deal screening and portfolio monitoring processes and without demonstrating ESG readiness, many startups may not even reach the term sheet stage. For IPO-bound start ups, the stakes are even higher—ESG now influences valuation premiums, investor confidence and post-listing reputation. According to the Journal of Economics & Management (2025), top quartile ESG performers saw significantly less underpricing on the day of their US IPOs. In India too, ESG metrics are now appearing in draft red herring prospectuses, with investors scrutinizing everything, from board structure to climate resilience. On the regulatory front, the Securities and Exchange Board of India (SEBI) has introduced the BRSR Core framework to enhance disclosures for the top 1,000 listed companies (by market capitalization). While the framework is aimed at public companies, its ripple effects extend beyond the listed space, intensifying apply once listed. Second, startups that serve as vendors or partners to listed firms should prepare to share ESG data as part of value chain reporting. Startups don't need to adopt complex frameworks overnight, but they do need a starting point. Materiality assessments, which identify the ESG issues most relevant to their sector and stakeholders, can offer the clarity and direction needed at the onset. It is time for India's startup ecosystem to lead not just in scale, but in sustainability. Founders who embed ESG early won't just meet expectations—they will define them.
